secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0001232524-22-000034
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma Q2 revenue $932.9M (+24% YoY), affirms FY2022 guidance, net leverage target met early
--------------------------------------------------------------------------------

- Q2 2022 total revenues $932.9M, up 24% YoY; strong commercial execution across franchises.
- 2022 total revenue guidance affirmed at $3.5-3.7B; GAAP guidance updated for FX movements.
- Net leverage ratio 3.2x, achieving target six months ahead of schedule, providing balance sheet flexibility.
- Milestones: more patients on Xywav than Xyrem; JZP458 MAA submitted to EMA; JZP815 IND cleared by FDA.
- Divested Sunosi to sharpen focus on strategic priorities; pipeline expanded with JZP441 and JZP898.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252422000034/0001232524-22-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252422000034/jazz-20220803.htm
  HTML page:      https://secwatch.observer/filing/0001232524-22-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer